Investor Update Teleconference
MELBOURNE, Australia, and MENLO PARK, California U.S.A
July 04, 2005
ChemGenex Pharmaceuticals Limited (ASX: CXS, NASDAQ: CXSP) will host an Investor Update Teleconference on Wednesday, July 6th 2005 at 11:00am (AEST).
You are cordially invited to participate in this live conference call with Dr. Greg Collier, Chief Executive Officer and Managing Director. Dr. Collier will be providing an updated overview of the company following its recent NASDAQ listing and the signing of the alliance with Stragen Pharma. Questions from participants will be taken following the update.
Details of toll free dial in numbers are as follows:-
Operator Assisted Toll-Free Dial-In Number: 1800766788
Operator Assisted International Dial-In Number: +61 (0)2 82287003
International Toll Free Dial-in Number(s):
| Brazil : | 00081562037961 |
| Thailand : | 00180061350226 |
| Indonesia : | 00180306130245 |
| Japan : | 00531250011 |
| Korea (South) : | 0079861350577 |
| Taiwan : | 00801615105 |
| Sweden : | 0200285431 |
| Germany : | 08001825033 |
| Austria : | 0800281482 |
| New Zealand : | 0800445474 |
| United Kingdom : | 08007318027 |
| China : | 108001400354 |
| Malaysia : | 1800804631 |
| United States : | 18663211799 |
| Canada : | 18666384709 |
| Norway : | 80016164 |
| Singapore : | 8006163017 |
| Hong Kong : | 800901499 |
| South Africa : | 800998256 |
Please visit our website www.chemgenex.com for a recording of the update following the teleconference.
About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a gene-based pharmaceutical company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex currently has two compounds in Phase 2 clinical trials, CeflatoninŽ for leukemia and QuinamedŽ for solid tumors, and has a significant portfolio of anti-cancer, diabetes, obesity and depression programs. The company's diabetes and obesity program is partnered with Merck KGaA and the depression program is partnered with Vernalis plc. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and the NASDAQ exchange under the symbol "CXSP".
Contacts
| Dr. Greg Collier (CEO and Managing Director) |
Australia +61 3 5227 2752
USA +1 650 474 9800 ext 103 |
| Dr. Dennis Brown (President and Director) |
USA +1 650 474 9800 ext 108
Australia +61 3 5227 2703 |
| Mr. Hershel Berry (Investor Relations) |
Australia +61 3 5227 2703
USA (415) 392-3310 |
Safe Harbor Statement
Certain statements made herein that use the words "estimate," 'project," "intend," "expect," "believe," and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development , the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
